Payment overview · 2025
General Payments
$1,354.34
55 reported records · 19 companies
Healthcare provider profile · identity verified
Lisa Weldon, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · VALDOSTA, GA · NPI 1538470851
Verified facts
What the public records show
CMS Open Payments records show Lisa Weldon, NP received $1,354.34 in general payments during 2025 across 55 reported records.
UCB, Inc. accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $324.70 | 24.0% | 13 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $121.83 | 9.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.76 | 8.6% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $116.42 | 8.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.18 | 7.4% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $97.95 | 7.2% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$84.72 | 6.3% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $75.04 | 5.5% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.88 | 3.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $51.10 | 3.8% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $34.28 | 2.5% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $30.70 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.13 | 2.1% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$27.96 | 2.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.10 | 1.7% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $20.91 | 1.5% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $17.17 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.43 | 1.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $15.08 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,307.35 | 54 |
| Education | $46.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $124.36 | 5 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $121.83 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $116.76 | 5 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $116.42 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.18 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.18 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $86.96 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $84.72 | 4 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $75.04 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $72.76 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $64.55 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $51.88 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $51.10 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $33.40 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $30.70 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
220 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
200 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
121 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 336 | 79 |
| Farxiga | Dapagliflozin Propanediol | 220 | 49 |
| Mounjaro | Tirzepatide | 200 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 185 | 50 |
| Metformin Hcl Er | Metformin Hcl | 183 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 171 | 53 |
| Nateglinide | Nateglinide | 161 | 40 |
| Jardiance | Empagliflozin | 153 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 34 |
| Metformin Hcl | Metformin Hcl | 127 | 35 |
| Trulicity | Dulaglutide | 121 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 44 |
| Losartan Potassium | Losartan Potassium | 108 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 89 | 35 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 76 | 24 |
| Lisinopril | Lisinopril | 68 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 67 | 21 |
| Gabapentin | Gabapentin | 62 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 58 | 27 |
| Vascepa | Icosapent Ethyl | 56 | 12 |
| Humalog | Insulin Lispro | 55 | 18 |
| Synthroid | Levothyroxine Sodium | 55 | 13 |
| Novolog Flexpen | Insulin Aspart | 51 | 20 |
| Insulin Lispro | Insulin Lispro | 50 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 16 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 41 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 37 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Praluent Pen | Alirocumab | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | 12 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,354.34 · 55 records | UCB, Inc. | AMPYRA, AUSTEDO XR, Briviact, Dysport, FYCOMPA, Fintepla, Gamunex-C, Gocovri, Hizentra, INBRIJA, KISUNLA, Leqembi, NURTEC ODT, Nayzilam, Rystiggo, ULTOMIRIS, VALTOCO, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, XYWAV, Xeomin, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error